CLRB Cellectar Biosciences

Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September

Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September

FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating officer at Cellectar Biosciences, will participate in panel discussions and present at multiple medical meetings and industry conferences in September.

Details are as follows:

ADC and Novel Conjugates Partnering and Investment Summit

Title:ADCs x Radioligands: The Use of One Technology to Advance the Other
Date/Time:September 9, 2025, 9:30 AM ET



BioProcess International

Title:ADCs and Beyond in Radiopharmaceuticals
Date/Time:September 15, 2025, 11:30 AM ET



Targeted Radiopharmaceuticals (TRP) Supply Chain and Manufacturing

Title:Addressing Barriers in Supply Chains to Ensure Reliable Isotope Access & Consistent Patient Delivery
Date/Time:September 24, 2025, 9:30 AM ET
  
Title:Addressing Facility Downtime & Regulatory Delays by Designing Robust Infrastructure Strategy to Accelerate Safe, Scalable Radiopharmaceutical Manufacturing
Date/Time:September 24, 2025, 12:10 PM ET
  
Title:Impact of Isotope Half-Life: Long-vs. Short-Lived Radiotherapeutics and Differences in Manufacturing, Quality & Distribution to Clinic
Date/Time:September 24, 2025, 1:30 PM ET



American Association for Cancer Research Special Conference in Cancer Research: Discovery and Innovation in Pediatric Cancer – From Biology to Breakthrough Therapies

Title:Precision Radiotherapy for Incurable Brain Tumors: Phase 1b Dose & Regimen Optimization Study of Iopofosine I 131 in Inoperable Relapsed or Refractory Pediatric High-Grade Glioma, Interim Data Assessment
Session:Plenary Session 3: From Targets to Trials: Rethinking How We Design Child-First Medicine
Date/Time:September 26, 2025, 2:50 PM ET



American Association for Cancer Research Special Conference in Cancer Research: Advances in Pancreatic Cancer Research – Emerging Science Driving Transformative Solutions

Title:Targeting Lipid Rafts in Hypoxic Pancreatic Ductal Adenocarcinoma: Preclinical Evaluation of [225Ac]CLR 121225, a Novel Actinium-Based Radio-Conjugate
Date/Time:September 30, 2025, 6:00 – 9:00 PM ET



About Cellectar Biosciences, Inc.

Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.

The company’s product pipeline includes its lead assets: iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope); CLR 121225, an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer; and CLR 121125, an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.

In addition, iopofosine I 131 has been studied in Phase 2b trials for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, and the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has also granted iopofosine I 131 six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications.

For more information, please visit  or join the conversation by liking and following us on the company’s social media channels: , , and .

Investor Contact:

Anne Marie Fields

Precision AQ

212-362-1200



EN
05/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cellectar Biosciences

 PRESS RELEASE

Cellectar and Evestia Clinical Announce Partnership to Support Auger-E...

Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC) Intends to Initiate Phase 1b Clinical Trial in TNBC at Mayo Clinic in Fourth Quarter 2025 FLORHAM PARK, N.J. and LONDON and CHARLOTTESVILLE, Va., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (“Cellectar”) (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and Evestia Clinical (“Evestia”), a leading independent global specialist ...

 PRESS RELEASE

Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Act...

Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225 Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid Tumors FLORHAM PARK, N.J. and GARCHING, Germany and MUNICH, Germany, Sept. 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CLRB, “Cellectar”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and , a leading radiopharmaceutical biotech company, today announced a supply agreement for Actinium-225 (Ac-225). The agreement will support the clinical...

 PRESS RELEASE

Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targete...

Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit Highlighting Continued Progress with EMA Regarding a Potential Conditional Marketing Authorization Submission for Iopofosine I 131 to Treat Waldenstrom Macroglobulinemia (WM) in the EU; Decision on Track for Late 3Q25/Early 4Q25 Intention to Pursue an Accelerated Approval with the U.S. Food and Drug Administration for Iopofosine I 131 as a Treatment for WM Advancing Auger-Emitting Radiopharmaceutical Product Candidate into Phase 1b Clinical Trial for the Treatment of Tr...

 PRESS RELEASE

Cellectar Biosciences to Participate in Multiple Upcoming Medical Meet...

Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating officer at Cellectar Biosciences, will participate in panel discussions and present at multiple medical meetings and industry conferences in September. Details are as follows: ADC and Novel Conjugates ...

 PRESS RELEASE

Cellectar Biosciences to Present Data in Poster Presentation at the Am...

Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for poster presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research taking place September 28...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch